IPA and RIBOPRO: Revolutionizing Immunotherapy with mRNA-Driven Antibody Discovery

In the rapidly evolving landscape of immunotherapy, two leading players, Integrated Protein Technologies (IPA) and RIBOPRO, have joined forces to advance mRNA-driven antibody discovery. This strategic partnership aims to unlock new frontiers in the treatment of orthopoxvirus infections and other emerging viruses, offering significant advantages in speed, cost, and flexibility.

IPA, a renowned expert in antibody discovery, has developed the LNP-mRNA platform, which enables the rapid production of neutralizing antibodies against orthopoxviruses. This platform has demonstrated remarkable success in generating antibodies with broad neutralization activities against variola virus (VARV) and monkeypox virus (MPXV), as well as other orthopoxviruses (IPA, 2025). By combining this platform with RIBOPRO's expertise in antibody engineering, the partnership can generate tailored mRNA antibody combinations that target both intracellular mature virus (IMV) and extracellular enveloped virus (EEV) forms, providing superior in vivo protection (IPA, 2025).

The collaboration between IPA and RIBOPRO offers several potential advantages over conventional antibody production methods. Firstly, the use of mRNA-encoded antibodies allows for rapid production and administration, as demonstrated in a study where a single intravenous injection of LNP-encapsulated mRNA antibody in mice resulted in the rapid production of neutralizing antibodies (Abstract). This speed is crucial for addressing emerging infectious diseases or bioterrorism threats, where a quick response is essential.

Secondly, the high cost of antibody engineering and manufacturing processes is a significant barrier to developing therapeutic antibodies against orthopoxviruses (Abstract). mRNA-encoded antibodies have emerged as a powerful and universal platform for rapid antibody production, potentially reducing the overall cost of antibody development and manufacturing.

Lastly, the mRNA platform allows for the construction of multiple mRNA combinations encoding monoclonal antibodies with broad neutralization activities against orthopoxviruses (Abstract). This flexibility enables the creation of tailored mRNA antibody combinations, such as the unique mRNA antibody cocktail Mix2a, which targets both IMV and EEV forms of viruses (Abstract). The ability to create custom mRNA antibody combinations allows for a more targeted and adaptable approach to combating various orthopoxvirus strains and emerging viruses.



The collaboration between IPA and RIBOPRO can significantly impact the future of immunotherapy by enabling the rapid, scalable, and cost-effective production of tailored mRNA antibody combinations with broad-spectrum protection against orthopoxvirus infections and other emerging viruses. This partnership can help address the urgent need for effective therapeutic strategies to combat emerging viral threats and improve global health security.

In conclusion, the partnership between IPA and RIBOPRO represents a significant advancement in the field of immunotherapy, offering a powerful and adaptable approach to combating orthopoxvirus infections and other emerging viruses. By leveraging the strengths of both companies in antibody engineering and mRNA technology, this collaboration can revolutionize the development of therapeutic antibodies and improve global health security.

Word count: 598